Purpose
=======

In 2009, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) established a longitudinal multi-center, multiple disease U.S. national registry (CARRAnet) for pediatric rheumatology with the intent of providing 60 participating clinical sites a new framework to drive observational clinical research and evidence-based care. CARRAnet seeks to enroll up to 20,000 subjects with childhood-onset rheumatic disease and twice yearly follow-up. We report baseline characteristics of the initial 6-month enrollment cohort; disease-specific results are reported separately.

Methods
=======

Enrollment commenced 5/29/2010 with data available through 12/28/10. Inclusion criteria comprised 1 of 8 categories of defined rheumatic disease with onset before the 16^th^ birthday in subjects \<=21 years (localized scleroderma, juvenile dermatomyositis, juvenile idiopathic arthritis, juvenile primary fibromyalgia syndrome, SLE or mixed connective tissue disease, sarcoidosis, systemic sclerosis, and vasculitis). A common baseline data set and 1 disease-specific data set was completed on each participant by interview and chart review. Data cleaning and analysis employed Microsoft Excel and Access (Microsoft Corp), SAS (SAS Institute), and R (R Foundation for Statistical Computing).

Results
=======

1638 subjects were enrolled from 27 centers throughout the US. The analysis cohort reflected 1371 subjects, predominantly JIA; 63 variables were collected for the shared baseline form with summary statistics presented in the figures. The population reported overall good to excellent health by patient and physician report: 96% with mean HRQOL good to excellent; physician mean global assessment of disease activity (PGAS) 1.6 (0-10 scale). PGAS correlated with subject reports (CHAQ, subject global, subject pain scores -- Pearson corr 0.33, 0.39, 0.42 respectively). Medication use was prevalent, including 74% ever on steroids, 41% ever on biologics, and 31% currently on biologics. Growth was within normal on average, but exhibited wide deviation (-5.3\>weight Z \> 4.7, -19.7\>height Z\>9.4). A similarly wide range was seen on both objective and subjective measures, identifying probable subpopulations with high disease activities.

###### 

Summary characteristics of CARRAnet initial cohort

  Demographic measures                                 N (%)
  ---------------------------------------------------- ----------------------
  Total participants studied                           1371
  Female gender                                        1024 (75%)
  White/caucasian                                      1187 (87%)
  Age at onset of symptoms, mean in years              7.2
  Age at baseline visit, mean in years                 11.8
  Black or African American                            127 (9%)
  Asian                                                45 (3%)
  American Indian or Alaska Native                     30 (2%)
  Native Hawaiian or Pacific Islander                  9 (\<1%)
  Hispanic ethnicity                                   150 (11%)
                                                       
  **Primary rheuamtic diagnosis**                      
  Juveline idiopathic arthritis                        1051 (77%)
  Juveline dematophyositis                             109 (8%)
  Systemic lupus erythematosus                         100 (7%)
  Localized scleroderma                                43 (3%)
  Mixed connective tissue disease                      23 (2%)
  Vasculitis                                           23 (2%)
  Systemic sclerosis                                   9 (\<1%)
  Sarcoidosis                                          8 (\<1%)
  Juveline primary fibromyalgia syndrome               6 (\<1%)
                                                       
  **Growth parameters**                                **Mean & (Range)**
  Weight Z-score                                       0.28 (-5.3 -- 4.7)
  Height Z-score                                       -0.14 (-19.7 -- 9.4)
  BMI Z-score                                          0.38 (-5.0 -- 4.1)
                                                       
  **Assessments (scale: best -\> worst)**              **Mean & (Range)**
  Physician global assess disease activity (0 -- 10)   1.6 (0 -- 10)
  Subject global assess disease activity (0 -- 10)     2.3 (0 -- 10)
  Subject pain score (0 -- 10)                         2.4 (0 -- 10)
  CHAQ (0 -- 3)                                        0.33 (0 -- 3)
  HRQOL -- Good, very good, excellent (%)              96%
  HRQOL -- Very poor, poor (%)                         3%
                                                       
  **Family history (first degree relative) of**        **N (%)**
  Psoriasis                                            82 (6%)
  Rheumatoid arthritis                                 71 (5%)
  Autoimmune throiditis                                62 (5%)
  Fibromyalgia                                         61 (4%)
  Juvenile idiopathic arthritis                        55 (4%)
  Diabetes type I                                      35 (3%)
  Inflammatory bowel disease                           31 (2%)
  Systemic lupus erthematosus                          28 (2%)
  Spondyloarthritis or ankyl. spondylitis              16 (1%)
  Multiple sclerosis                                   13 (1%)
  Celiac disease                                       10 (1%)
  Uveitis                                              5 (\<1%)
                                                       
  **Medication use**                                   **N (%)**
  Steroids (ever)                                      1010 (74%)
  Steroids (longterm daily, ever)                      644 (47%)
  Steroids (IV pulse, ever)                            212 (15%)
  Steroids (IA, ever)                                  529 (39%)
  Biologics (ever)                                     560 (41%)
  Biologics (current)                                  429 (31%)
  TNF-α Blockers (current)                             338 (25%)
  DMARDs (ever)                                        1107 (81%)
  DMARDs (current)                                     1021 (75%)
  Methotrexate (current)                               620 (45%)
  NSAIDs (current)                                     625 (46%)
  Opioids (current)                                    17 (1%)
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Conclusion
==========

The initial CARRAnet cohort reflects predominantly low disease activity with favorable self-reports. This is not a population study and issues of enrollment bias require further investigation. Despite the overall well-being of the population, the high use of steroids, biologics, and DMARDs, along with significant subpopulations concerning for high disease activity, are important areas of future focus.
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